Bisphosphonate prodrugs: Synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid

Journal of Medicinal Chemistry

Volumn 42, Issue 24, 1999, Pages 5053-5058

  Niemi, Riku ^a   Vepsäläinen, Jouko ^a,b   Taipale, Hannu ^a   Järvinen, Tomi ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Finncovery Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BUFFER; CLODRONIC ACID; P,P' BIS[3 (PHENYLMETHANOYLOXY)PROPYL](DICHLOROMETHYLENE)BISPHOSPHONATE DIPIPERIDINIUM SALT; P,P' DI(PIVALOYLOXYMETHYL)(DICHLOROMETHYLENE)BISPHOSPHONATE DIPIPERIDINIUM SALT; PRODRUG; TETRA(PIVALOYLOXYMETHYL)(DICHLOROMETHYLENE)BISPHOSPHONATE; TETRAKIS[3 (PHENYLMETHANOYLOXY)PROPYL](DICHLOROMETHYLENE)BISPHOSPHONATE; TRI(PIVALOYLOXYMETHYL)(DICHLOROMETHYLENE)BISPHOSPHONATE N,N,N TRIETHYL N (PIVALOYLOXYMETHYL)AMMONIUM SALT; TRIS[3 (PHENYLMETHANOYLOXY)PROPYL](DICHLOROMETHYLENE)BISPHOSPHONATE PIPERIDINIUM SALT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIPID SOLUBILITY; LIVER HOMOGENATE; NONHUMAN; PARTITION COEFFICIENT; RABBIT; REACTION ANALYSIS; SERUM;

ANIMALS; BENZOATES; BIOLOGICAL AVAILABILITY; BLOOD; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHEMISTRY, PHYSICAL; CLODRONIC ACID; DIPHOSPHONATES; DRUG STABILITY; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INTESTINAL ABSORPTION; LIVER; PHOSPHODIESTERASE I; PHOSPHORIC DIESTER HYDROLASES; PRODRUGS; RABBITS; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0345669115     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991109o     Document Type: Article

References (36)

1. Fleisch, H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient; The Parthenon Publishing Group Inc.: New York, 1995.
2. Lin, J. H. Bisphosphonates: A Review of Their Pharmacokinetic Properties. Bone 1996, 18, 75-85.
3. Rodan, G. A.; Fleisch, H. A. Bisphosphonates: Mechanisms of Action. J. Clin. Invest. 1996, 97, 2692-2696.
4. Yakatan, G. J.; Poynor, W. J.; Talbert, R. L.; Floyd, B. F.; Slough, C. L.; Ampulski, R. S.; Benedict, J. J. Clodronate Kinetics and Bioavailability. Clin. Pharm. Ther. 1982, 31, 402-410.
5. Pentikäinen, P. J.; Elomaa, I.; Nurmi, A.-K.; Kärkkäinen, S. Pharmacokinetics of Clodronate in Patients with Metastatic Breast Cancer. Int. J. Clin. Pharm. Ther. Toxicol. 1989, 27, 222-228.
6. Stella, V. J.; Charman, W. N. A.; Naringrekar, V. H. Prodrugs. Do They Have Advantages in Clinical Practice? Drugs 1985, 29, 455-473.
7. Waller, D. G.; George, C. F. Prodrugs. Br. J. Clin. Pharmacol. 1989, 28, 497-507.
8. Björkroth, J.-P.; Pakkanen, T. A.; Lindroos, J.; Pohjola, E.; Hanhijärvi, H.; Lauren, L.; Hannuniemi, R.; Juhakoski, A.; Kippo, K.; Kleimola, T. Comparative Molecular Field Analysis of Some Clodronic Acid Esters. J. Med. Chem. 1991, 34, 2338-2343.
9. Ahlmark, M. J.; Vepsäläinen, J. J. Strategies for the Selective Synthesis of Monosubstituted (Dichloromethylene)Bisphosphonate Esters. Tetrahedron 1997, 53, 16153-16160.
10. Niemi, R.; Taipale, H.; Ahlmark, M.; Vepsäläinen, J.; Järvinen, T. Simultaneous Determination of Clodronate and Its Partial Ester Derivatives by Ion-Pair Reversed-Phase High-Performance Liquid Chromatography Coupled with Evaporative Light Scattering Detection. J. Chromatogr. B 1997, 707, 97-102.
11. Niemi, R.; Pennanen, H.; Vepsäläinen, J.; Taipale, H.; Järvinen, T. Bisphosphonate Prodrugs: Synthesis and In Vitro Evaluation of Novel Partial Amides of Clodronic Acid. Int. J. Pharm. 1998, 174, 111-115.
12. Ahlmark, M.; Vepsäläinen, J.; Taipale, H.; Niemi, R.; Järvinen, T. Bisphosphonate Prodrugs: Synthesis and In Vitro Evaluation of Novel Clodronic Acid Dianhydrides as Bioreversible Prodrugs of Clodronate. J. Med. Chem. 1999, 42, 1473-1476.
13. Krise, J. P.; Stella, V. J. Prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Deliv. Rev. 1996, 19, 287-310.
14. Starrett, J. E.; Tortolani, D. R.; Russell, J.; Hitchcock, M. J. M.; Whiterock, V.; Martin, J. C.; Mansuri, M. M. Synthesis, Oral Bioavailability Determination, and In Vitro Evaluation of Prodrugs of the Antiviral Agent 9-(2-(Phosphonomethoxy)ethyl)Adenine (PMEA). J. Med. Chem. 1994, 37, 1857-1864.
15. Serafinowska, H. T.; Ashton, R. J.; Bailey, S.; Harnden, M. R.; Jackson, S. M.; Sutton, D. Synthesis and In Vivo Evaluation of Prodrugs of 9-(2-(Phosphonomethoxy)ethoxy)Adenine. J. Med. Chem. 1995, 38, 1372-1379.
16. Shaw, J.-P.; Sueoka, C. M.; Oliyai, R.; Lee, W. A.; Arimilli, M. N.; Kim, C. U.; Cundy, K. C. Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(Phosphonomethoxy)-propyl]Adenine (PMPA) in Dogs. Pharm. Res. 1997, 14, 1824-1829.
17. Iyer, R. P.; Phillips, L. R.; Biddle, J. A.; Thakker, D. R.; Egan, W.; Aoki, S.; Mitsuya, H. Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral, Trisodium Phosphonoformate (Foscarnet Sodium). Tetrahedron Lett. 1989, 30, 7141-7144.
18. Atack, J. R.; Prior, A. M.; Fletcher, S. R.; Quirk, K.; McKernan, R.; Ragan, C. I. Effects of L-690,488, a Prodrug of the Bisphosphonate Inositol Monophosphatase Inhibitor L-690,330, on Phosphatidylinositol Cycle Markers. J. Pharmacol. Exp. Ther. 1994, 270, 70-76.
19. Farquhar, D.; Khan, S.; Srivastva, D. N.; Saunders: P. P. Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2′-Deoxy-5-Fluorouridine 5′-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells. J. Med. Chem. 1994, 37, 3902-3909.
20. Annaert, P.; Kinget, R.; Naesens, L.; de Clercq, E.; Augustijns, P. Transport, Uptake, and Metabolism of the Bis(pivaloyloxymethyl)-ester Prodrug of 9-(2-Phosphonylmethoxyethyl)Adenine in an In Vitro Cell Culture System of the Intestinal Mucosa (Caco-2). Pharm. Res. 1997, 14, 492-496.
21. Vepsäläinen, J. Bisphosphonate Prodrugs: A New Synthesis Strategy to Tetraacyloxymethyl Esters of Methylenebisphosphonates. Tetrahedron Lett. (accepted).
22. Vepsäläinen, J. J.; Kivikoski, J.; Ahlgren, M.; Nupponen, H. E.; Pohjola, E. K. An Improved Synthetic Method and the First Crystal Structures for (Dihalomethylene)Bisphosphonate Partial Esters. Tetrahedron 1995, 51, 6805-6818.
23. Choudary, B. M.; Reddy, P. N. Vanadium-catalyzed Oxidative Ring Cleavage of Cyclic Acetals. A Facile Synthesis of Glycol Monoesters. Synlett 1995, 959-960.
24. Daignault, R. A.; Eliel, E. L. 2-Cyclohexyloxyethanol. Org. Syntheses 1973, Coll. Vol. 5, 303-306.
25. Althoff, W.; Fild, M.; Schmutzler, R. Synthesis and NMR Studies of Alkylene/Alkylidene Bis(phosphonic dihalides) and -Bis(fluorophosphoranes). Chem. Ber. 1981, 114, 1082-1090.
26. Friis, G. J.; Bundgaard, H. Design and Application of Prodrugs. In A Textbook of Drug Design and Development, 2nd ed.; Krogsgaard-Larsen, P., Liljefors, T., Madsen, U., Eds.; Harwood Academic Publishers GmbH: Amsterdam, 1996; pp 351-385.
27. Krisch, K. Carboxylic Ester Hydrolases. In The Enzymes; Boyer, P. D., Ed.; Academic Press: New York, 1971; Vol. 5, p 57.
28. Nielsen, N. M.; Bundgaard, H. Prodrugs as Drug Delivery Systems. 68. Chemical and Plasma-Catalyzed Hydrolysis of Various Esters of Benzoic Acid: A Reference System for Designing Prodrug Esters of Carboxylic Acids. Int. J. Pharm. 1987, 39, 75-85.
29. Vepsäläinen, J.; Nupponen, H.; Pohjola, E.; Ahlgren, M.; Vainiotalo, P. Bisphosphonic Compounds. Part 3. Preparation and Identification of Tetraalkyl Methylene- and (α-Halomethylene)Bisphosphonates by Mass Spectrometry, NMR Spectroscopy and X-ray Crystallography. J. Chem. Soc., Perkin Trans. 2 1992, 835-842.
30. Järvinen, T.; Suhonen, P.; Urtti, A.; Peura, P. O,O′-(1,4-Xylylene) Bispilocarpic Acid Esters as New Potential Double Prodrugs of Pilocarpine for Improved Ocular Delivery. II. Physicochemical Properties, Stability, Solubility and Enzymatic Hydrolysis. Int. J. Pharm. 1991, 75, 259-269.
31. Lambert, W. J. Modeling Oil-Water Partitioning and Membrane Permeation Using Reversed-Phase Chromatography. J. Chromatogr. A 1993, 656, 469-484.
32. Minick, D. J.; Frenz, J. H.; Patrick, M. A.; Brent, D. A. A Comprehensive Method for Determining Hydrophobicity Constants by Reversed-Phase High-Performance Liquid Chromatography. J. Med. Chem. 1988, 31, 1923-1933.
33. Hsieh, M.-M.; Dorsey, J. G. Bioavailability Estimation by Reversed-Phase Liquid Chromatography: High Bonding Density C-18 Phases for Modeling Biopartitioning Processes. Anal. Chem. 1995, 67, 48-57.
34. Nolen, H. W.; Friend, D. R. Menthol-β-D-Glucuronide: A Potential Prodrug for Treatment of the Irritable Bowel Syndrome. Pharm. Res. 1994, 11, 1707-1711.
35. Singh, P.; Roberts, M. S. Local Deep Tissue Penetration of Compounds after Transdermal Application: Structure-Tissue Penetration Relationships. J. Pharmacol. Exp. Ther. 1996, 279, 908-917.
36. Friend, D.; Catz, P.; Heller, J.; Reid, J.; Baker, R. Transdermal Delivery of Levonorgestrel II: Effect of Prodrug Structure on Skin Permeability In Vitro. J. Controlled Release 1988, 7, 251-261.